Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31359865 | 1.00 | LPL (0.38) | LPLLIPGESR2GRM2F2 | |
| SCHEMBL30935365 | 0.92 | LPL (0.38) | LPLLIPGESR2F2F11 | |
| SCHEMBL12327209 | 0.84 | LIPG (0.44) | LPLLIPGESR2F11CA1 | |
| SCHEMBL1667913 | 0.83 | ALDH1A1 (0.49) | LPLLIPGESR2CA1CA2 | |
| SCHEMBL21452293 | 0.80 | LPL (0.41) | LPLLIPGF2F11PRSS1 | |
| SCHEMBL21434075 | 0.80 | LPL (0.41) | LPLLIPGF2F11PRSS1 | |
| SCHEMBL17365883 | 0.80 | LPL (0.45) | LPLLIPGF2F11PRSS1 | |
| SCHEMBL24094187 | 0.80 | LPL (0.41) | LPLLIPGESR2CA1CA2 | |
| SCHEMBL1293588 | 0.80 | XDH (0.41) | LPLLIPGESR2 | |
| SCHEMBL13089216 | 0.79 | LPL (0.41) | LPLLIPGESR2F2F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340563-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | TAKEDA DEVELOPMENT CENTER AMERICAS, INC. | 2025-11-06 | — | — | US | disclosed |
| WO-2023194964-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | WO | disclosed |
| EP-2963043-B1 | TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-2963043-B1 | TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9458176-B2 | Tetrahydroimidazo(1,5-D)[1,4]oxazepine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| US-9458176-B2 | Tetrahydroimidazo(1,5-D)[1,4]oxazepine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| US-9458176-B2 | Tetrahydroimidazo(1,5-D)[1,4]oxazepine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| EP-2963043-A1 | TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2016-01-06 | — | — | EP | disclosed |
| WO-2014133022-A1 | TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE | エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) | 2014-09-04 | — | — | WO | disclosed |
| US-20140243316-A1 | Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243316-A1 | Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243316-A1 | Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340563-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | NLRP3, NLRP1, NOD1 | LPL 3144/4885LIPG 4256/4885ESR2 1456/4885 |
| US-20140243316-A1 | Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative | GRM2, GRM1, GRIA2 | LPL 4001/4885LIPG 4467/4885ESR2 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.